trial · primary record
Tafasitamab
Autoimmune Disorders
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 47 |
| Primary completion | 2030-12-31 |
| Primary endpoint | Adverse Event |
| Registry ID | NCT06434363 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:52.339Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06434363
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.